Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
for Hemophilia A
Sponsor: AryoGen Pharmed Co.
Sex: Male·Age: 2+
Code: NCT07791836·Not Yet Recruiting·Listed Aug 28, 2026